Under hæmodialyse kan patienter som behandles med Dynepo, få brug for øget antikoalgulationsbehandling, for at forhindre koagulation af den arteriovenøse anastomose.
ed The use of Dynepo in nephrosclerotic patients not yet undergoing dialysis should be defined individually, as a possible acceleration of progression of renal failure cannot be ruled out with certainty.